1) Naomaikang capsules (NMKC)
脑脉康片
1.
Objective: To evaluate efficacy of Chinese Compound Prescription-Naomaikang capsules (NMKC) by pharmacology research and provide foundation for clinical trials and application.
目的：通过主要药效学研究，客观评价脑脉康片的有效性，并初步探讨其防治脑动脉硬化的作用机制，为临床研究提供依据。
2) Naomaikang
脑脉康
1.
Study on the relation of brain-derived neurotrophic factor, basic fibroblast growth factor expressio n and apoptosis of neuron in rats following focal cerebral ischemia/reperfusion and effect of Naomaikang on it;
脑缺血-再灌注后BDNF和bFGF表达与神经元凋亡的关系及脑脉康的干预作用
2.
Effects of Naomaikang on the Platelet Aggregation Rate and Pathomorphological Changes of Experimental Atherosclerosis Rabbits;
脑脉康对动脉粥样硬化家兔血小板聚集率和病理形态学的影响
3.
Primary Comparison of Absorption Content of Different Macroporous Absorbing Resin to Multiplexing Formulation Naomaikang Extract;
不同大孔吸附树脂对复方脑脉康提取物吸附容量初步比较
3) Nao Xue Kang Tablets
脑血康片
1.
The Chronic Toxicity Study on Nao Xue Kang Tablets in Rats(I) --A Observed Report on Urine and Reversible observe;
脑血康片对大鼠的长期毒性研究(I)——尿液与可逆性观察报告
4) Naoxinkang tablet
脑心康片
1.
Effect of Naoxinkang tablet on apoptosis-related gene Caspase-3 expression in rats with cerebral ischemia reperfusion injury
脑心康片对大鼠脑缺血再灌注损伤后凋亡相关基因Caspase-3表达的影响
5) Piracetam tablet
脑复康片
1.
Methods 58 cases who diagnosed with vascular dementia,Chinese Traditional Medicine fine for the gas deficiency and blood stasis,Tanzu patients were randomly divided into two groups:observation group with 30 patients(oral Bushen-Yiqi-Huayu capsule); control group with 28 cases (oral Piracetam tablet),Treatment course three-months.
方法将58例确诊为血管性痴呆、中医辨证为精气亏虚、血瘀痰阻的病人随机分成两组:观察组30例,口服补肾益气化瘀胶囊;对照组28例,口服脑复康片。
6) Yimaikang Tablets
益脉康片
1.
Determination of Scutellarin in Yimaikang Tablets by RP-HPLC;
RP-HPLC测定益脉康片中野黄芩苷的含量
补充资料：脑脉康
分子式：C19H26N6O6
分子量：暂无
CAS号：437-74-1
性质：暂无
制备方法：暂无
用途：适用于脑血栓形式等缺血性脑血管疾病及中风后遗症。
分子量：暂无
CAS号：437-74-1
性质：暂无
制备方法：暂无
用途：适用于脑血栓形式等缺血性脑血管疾病及中风后遗症。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条